Experience with second line drugs in frequently relapsing and steroid dependent childhood nephritic syndrome in a large Saudi center

Khalid Al-Saran, M.D. a, b, Khalid Mirza, M.D. c, *, Abdulhadi Al-Talhi, M.D. c, Esam Al-Kanani a

a Department of Pediatric Nephrology, King Saud Medical City (KSMC), Riyadh, Saudi Arabia
b College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia
c KSMC, Riyadh, Saudi Arabia

ARTICLE INFO

Article history:
Received 17 December 2016
Received in revised form 27 February 2017
Accepted 5 March 2017
Available online 22 March 2017

Keywords:
Levamisole
Cyclophosphamide
Mycophenolate Mofetil
Cyclosporine
Steroid dependent
Frequently relapsing
Prednisolone

ABSTRACT

Background and objectives: To assess the efficacy and safety of second line drugs used at our center in frequently relapsing and steroid dependent (FR/SD) childhood nephritic syndrome.

Patients and methods: This was a retrospective study over a period of 3 years (July 2012 to July 2015) on the use of 4 second line drugs in FR/SD nephrotic syndrome in children treated at our center. These drugs were Levamisole, Mycophenolate Mofetil (MMF), Cyclophosphamide, and Cyclosporine. We studied the relapse rate per year, cumulative dose of steroids, success, failure, and side effects of these drugs. Statistical analyses were done with the help of a statistician using the T-test and the “N-1” Chi–Square test.

Results: We reviewed the charts of 60 children. All had FR/SD nephrotic syndrome and received a 3 month protocol of prednisolone. 20 received Levamisole (33%), 12 received Cyclophosphamide (20%), 20 received MMF (25%), and 13 received Cyclosporine (22%).

All the four drugs significantly reduced the relapse rate and the cumulative dose of steroids (P < .0001). Treatment success was best with Cyclosporine (69.2%), and treatment failure was the least with Cyclosporine (7.6%). However, treatment success and failure with Cyclosporine when compared to other three drugs was not statistically significant. No dangerous side effects were seen with any of the 4 drugs in the observation period.

Conclusion: All the second line drugs in our study were equally effective. However, we recommend that the initial treatment of FR/SD nephrotic syndrome should be chosen with the least toxic yet equally efficacious drug Levamisole.

© 2017 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Idiopathic nephrotic syndrome (INS) occurs commonly between the ages of 1–6 years. The sex ratio is usually 2:1. The annual incidence of INS in children in USA and Europe has been estimated to 1–3 per 100,000 children below the age of 16 with a cumulative prevalence of 16 per 100,000 children [1]. Histopathologically, it could be minimal change, diffuse mesangial proliferation, or focal and segmental glomerulosclerosis. The International Study of Kidney Disease in Children (ISKDC) found minimal change in 76.6% of children with primary nephrotic syndrome [1].

90% of INS are steroid responsive and 10% are steroid resistant. Among the steroid responsive cases, 30% are cured after the initial episode, 10% are infrequent relapsers, and 60% are either frequent relapsers or steroid dependant or both [2]. This group of frequent relapsers and steroid dependant idiopathic nephrotic syndrome required repeated courses of corticosteroids which predisposes them to side effects of steroids such as stunted growth, hypertension, hyperglycemia, gastric hyperacidity and ulceration, osteoporosis, and metabolic bone disease.

In order to avoid steroid toxicity, certain second line drugs have been used. These are Levamisole, Cyclophosphamide, Mycophenolate mofetil, Cyclosporine, Tacrolimus, and Rituximab.

Levamisole is an immunostimulant and immunomodulator. It is
quite effective in reducing the relapse rate but after stopping it the relapses start occurring again. The most common side effect is reversible neutropenia but, its long-term safety is not well established. Oral cyclophosphamide is an alkylating agent which effectively suppresses the T-cells. Because of its serious side effects like bone marrow suppression, gonadal toxicity, and cancer, it is used with caution (not exceeding the cumulative dose). Mycophenolate mofetil is a T-cell immunosuppressant; its efficacy is dose dependent. A higher than the recommended dose is more effective in reducing the relapse rate but, its main drawback is that the relapses start occurring again as soon as it is stopped. As for its main side effect, it is diarrhea.

Calcineurin inhibitors (cyclosporine and tacrolimus) are effective T-cell immunosuppressants. They have a higher efficacy than the other previously mentioned drugs, but they carry serious side effects like nephrotoxicity, neurotoxicity, hypertension, hyperglycemia, and diabetes mellitus. Also, the patient relapses as soon as these drugs are stopped.

Recently, several reports described the efficacy and safety of rituximab in FR/SD INS. Rituximab is an anti-CD20 chimeric monoclonal antibody which effectively suppresses the B-cells leading ultimately to the suppression of T-cells.

Since it carries the risk of serious infection, it is currently reserved for difficult cases of FR/SD nephrotic syndrome.

Our study was an observational retrospective study on 4 commonly used second line drugs in FR/SD INS in children. The main aim was to compare the efficacy and safety of these 4 second line drugs so as to plan future prospective studies on second line drugs in FR/SD INS. The second aim was to develop a systematic approach and protocol of the use of these second line drugs in FR/SD INS.

2. Patients and methods

We reviewed the charts of children with FR/SD idiopathic nephrotic syndrome presenting to our center over a period of 3 years (July 2012 to July 2015).

2.1. Definitions

The definitions of nephrotic syndrome, remission, relapse, frequent relapse, and steroid dependent were as per the International Study of Kidney Disease in Children (ISKDC) (Table 1).

2.2. Treatment of first episode of nephrotic syndrome

All the patients received a 3-month protocol of corticosteroids as follows:

2.2.1. 3 Month protocol

Prednisolone 60 mg/m² [2] once daily (OD) x 6 weeks, followed by, 40 mg/m² [2] every other day (EOD) x 4 weeks, then, 20 mg/m² [2] EOD x 1 week, finally, 10 mg/m² [2] EOD x 1 week.

2.2.2. The treatment of relapses was as follows [3].

Prednisolone 60mg/m² [2] OD till urine protein was negative for 5 days, followed by, 40 mg/m² [2] EOD x 4 weeks, then, 30 mg/m² [2] EOD x 4 weeks, finally, 20mg/m² [2] EOD x 4 weeks.

2.2.3. Measurements

We recorded the following parameters weight, mean age at first episode, mean age at entry into study, serum creatinine, serum albumin, lipid profile, urine protein/creatinine ratio, at the first episode, at entry into the study, and at the end of the study. We also recorded the serum drug levels (Cyclosporine), number of relapses per year, and the cumulative dose of steroids before and after second line therapy. Calculation of cumulative dose of prednisolone was as follows: it was the total steroid dose over 1 year (in mg) adjusted to a surface area of 1 m².

2.2.4. The patients received the following second line drugs in the following doses

Levamisole 2.5 mg/kg EOD for 1 year, oral Cyclophosphamide 2 mg/kg x 12 weeks, Mycophenolate Mofetil (MMF) 1200 mg/m²/day in 2 divided doses for one year, and Cyclosporine 5 mg/kg/day in 2 divided doses for one year (Serum drug level 80–100 mg/ml). All these second line drugs were accompanied by low dose alternate day prednisolone.

2.2.5. Inclusion and exclusion criteria

2.2.5.1. Inclusion criteria

- All patients who had FR/SD idiopathic nephrotic syndrome.
- All patients who had received low dose prednisolone less than 0.75 mg/kg EOD initially for at least 1 year.

2.2.5.2. Exclusion criteria

- All patients of FR/SD who had received previous immunosuppressive drugs.
- All patients of steroid resistant syndrome.
- All patients of genetic nephrotic syndrome (e.g NPSH₂, NPSH₁).
- All patients of congenital or infantile nephrotic syndrome.

The following parameters were recorded and analyzed:

1. Mean relapse rate per year.
2. Mean cumulative dose of corticosteroids before, during, and after stopping second line drugs per year.
3. Treatment success was presented as the number and percentage of patients with complete absence of proteinuria with only low dose prednisolone, without second line drugs in the third year.

| Table 1 |
|---|
| Definitions. |
| Nephrotic syndrome: proteinuria $>$ 40 mg/h/m², $>$ 50 mg/kg/day, protein/creatinine ratio $>$ 0.2 g/mmol ($>$ 2 g/g), and hypoalbuminemia $<$ 25 g/L with or without edema |
| Steroid responsive: complete remission achieved with steroid therapy |
| Steroid resistant: failure to achieve remission following 4 week prednisolone 60 mg/m², followed by 3 methylprednisolone pulses |
| Relapse: proteinuria $>$ 40 mg/h/m², $>$ 50 mg/kg/day, Albustix+++ for 3 consecutive days after having been in remission |
| Frequent relapse: 2 or more relapses within 6 months of initial response for 4 or more relapses within a period of 1 year |
| Steroid dependence: 2 consecutive relapses during corticosteroid therapy or within 14 days after cessation of therapy |
| Early nonresponder: steroid resistance during the first episode |
| Late nonresponder: steroid resistance in a patient who had previously responded to corticosteroids therapy |
4. Treatment failure was presented as the and percentage of cases with recurrence of FR/SD in the third year who required other second line drugs to maintain remission.

Drugs were considered effective if they were able to reduce the relapse rate, cumulative dose of steroids, and those having a higher percentage of treatment success, and a lower percentage of treatment failure. The comparison was done before and after giving second line drugs.

2.2.6. Statistical analyses

Comparison of means was done using the T-test ($P < .05$ was taken significant result), and comparison of percentages was done using the “N-I” Chi square test with 95% confidence intervals [4,5].

3. Results

We reviewed the charts of 60 children with both frequent relapses and steroid dependency over a 3-year period. 20 (33.3%) cases received Levamisole for 1 year, 12 (20%) cases received oral Cyclophosphamide for three months, 15 (25%) cases received Mycophenolate Mofetil (MMF) for 1 year, and 13 (21.6%) cases received Cyclosporine for 1 year. For the first year, they received only low dose prednisolone. As for the second year, second line and low dose prednisolone, and only low dose prednisolone was given during the third year. Tables 2 and 3 show the baseline data upon initial episode and at the end of the third year. There was a significant change ($P < .0001$) in the urine protein/creatinine ratio, the mean serum albumin levels, and the mean cholesterol levels upon the initial episode of INS and at the end of the third year (Table 4).

3.1. Side effects

With Levamisole, 4 cases had transient neutropenia for which it was discontinued. When neutropenia resolved, it was restarted. With Cyclophosphamide, 3 cases had transient neutropenia and 1 hemorrhagic cystitis; the drug was restarted after they resolved. With cyclosporine, all cases had mild hirsutism and gum hyperplasia, 4 cases had mild hypertension, no cases had impaired renal function. With MMF, 3 cases had diarrhea. MMF dose was reduced and the diarrhea resolved. After that, MMF was resumed as before in half the dose initially and after 1–2 weeks, full dose was resumed. All the 4 drugs reduced the relapse rate and cumulative dose of steroids equally during therapy for 1 year and post therapy for another year ($P < .0001$).

4. Discussion

Various second line drugs have been used in children to treat FR/SD nephrotic syndrome. They include Levamisole, Cyclophosphamide, Mycophenolate Mofetil, Cyclosporine, Tacrolimus, and Rituximab. Several retrospective as well as prospective studies have been conducted on the use of these second line drugs [6–12]. On review of literature, there was no study so far on the comparison of the 4 second line drugs used in our study with each other.

In our study of 60 children, there were significant reductions in both the mean relapse rate and the cumulative dose of steroids with all 4 second line drugs ($P < .0001$). Treatment success was best with Cyclosporine (69.2%) and treatment failure was the least (76%). When compared to the other 3 drugs, these results were not significant. No major side effects were seen with any drug.

Sudha Ekambaram et al reported a retrospective study of 97 children with SDNS or FRNS. Levamisole was found to be effective in majority (77.3%), with better efficacy in children with FRNS as compared to those with SDNS. The mean cumulative steroid dose 1 year before therapy was 4109 (1154) mg/m², and 1 year post therapy was 661 (11) mg/m². The relapses were also less during the period of post Levamisole therapy. They did not observe any side effects even in those who completed 2 years of daily Levamisole therapy [6].

In our own prospective and controlled study on Levamisole versus low dose prednisolone, the relapse rate was reduced more significantly in the Levamisole group. It was reduced by 0.29 in the Levamisole group versus 0.11 relapses per patient per month in the control group. The mean cumulative dose of steroids was also reduced more significantly in the Levamisole group. It was reduced by 293 vs 102 mg/m²/month in the control group. Therapy failure was seen in 3/32 (9.4%) in Levamisole group versus 12/54 (50%) in the control group. No side effects of Levamisole were seen [7].

In a study on Levamisole, in FR/SD nephrotic syndrome by Madani et al, the steroid dose was significantly decreased (Mean reduction of 0.39 ± 0.46 g + 0.33±0.38 g) after treatment with Levamisole. The number of relapses also significantly decreased with a mean reduction of 0.92 ± 0.98 episodes to 1.07 ± 1.20 relapses per year. Their conclusion was that Levamisole appears to be effective in prolonging the duration of remission and decreasing the steroid dose in children with FR/SD nephrotic syndrome [8].

In a retrospective analysis of Levamisole vs. Cyclophosphamide by Alsaran K, no significant difference was seen in the efficacy of these 2 drugs in therapy of FR/SD nephrotic syndrome. Their recommendation was that Levamisole could replace Cyclophosphamide in this group of patients [9].

In a randomized control trial on MMF versus Levamisole by Basu B et al, MMF was associated with a higher rate of 12 month relapse.

### Table 2
The baseline data of all 60 patients upon initial episode.

| Mean Age ±SD upon initial episode | 3.75 years ± 1.1 yrs. |
| Mean Age ± SD at the start of second line drugs | 4.8 years ± 1.0 yrs. |
| Sex: Male/female ratio | 1:9:1 |
| Mean ± SD urine protein/creatinine ratio (mg/mmol) | Upon initial episode |
| Mean Serum Creatinine (µmol/L) | 1500 ± 160 |
| Mean Albumin ± SD (g/L) | 30 ± 5 |
| Mean cholesterol ± SD (mmol/L) | 18 g/L ± 5 |
| Mean triglyceride ± SD (mmol/L) | 5.8 ± 1.2 |
| Mean creatinine ± SD (mmol/L) | 2.0 ± 1 |

### Table 3
The baseline data at the end of the third year.

| Mean protein/creatinine ratio | 500 mg/mmol ± 80 |
| Mean serum creatinine | 32 µmol/L ± 2 |
| Serum albumin | 35 g/L ± 3 |
| Mean cholesterol ± SD | 4.0 ± 1 mmol/L |
| Mean triglyceride ± SD | 1.8 ± 1 mmol/L |
### Table 4

| Observations | Levamisole | Cyclophosphamide | MMF | Cyclosporine |
|--------------|------------|------------------|-----|--------------|
| Pre          | 1.6 (1.1)  | 1.0 (0.9)        | 4.0 (2.8) | 5.0 (4.0)   |
| During       | 0.7 (0.3)  | 1.8 (1.3)        | 0.6 (0.4) | 0.7 (0.5)   |
| Post         | 1.6 (1.1)  | 1.0 (0.9)        | 4.0 (2.8) | 5.0 (4.0)   |
| 1 yr         | 3.6 (2.5)  | 1.6 (1.0)        | 1.0 (0.1) | 4.0 (2.8)   |
| 1 yr post    | 1.0 (0.9)  | 1.0 (1.0)        | 0.7 (0.5) | 0.5 (0.4)   |
| 1 y post     | 2.0 (1.0)  | 0.5 (0.6)        | 1.0 (0.5) | 0.5 (0.4)   |
| 1 y post     | 2.0 (1.0)  | 0.5 (0.6)        | 1.0 (0.5) | 0.5 (0.4)   |
| 1 y post     | 2.0 (1.0)  | 0.5 (0.6)        | 1.0 (0.5) | 0.5 (0.4)   |
| 1 y post     | 2.0 (1.0)  | 0.5 (0.6)        | 1.0 (0.5) | 0.5 (0.4)   |

### References

1. Nephrotic syndrome in children. Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the international study of kidney disease in children. Kidney Int 1978;13(2):159–65.
2. Wingen AM, Muller-Wiefel DE, Scharer K. Spontaneous remissions in frequently relapsing and steroid dependant idiopathic nephrotic syndrome. Clin Nephrol 1985;23(1):35–40.
3. Gipson DS, Masengill SF. Management of childhood onset nephrotic syndrome. Pediatrics 2009;124:747.
4. Campbell I. Chi-squared and Fischer-Irwin tests of two-by-two tables with small sample recommendations. Stat Med 2007;26:3661–75 (Abstract).
Richard Son JTE. The analyses of 2X2 contingency tables- yet again. Stat Med 2011;30:890 [Abstract].

Sudha E, Vijaykumar M, Prabhalad N, Amish U, Sangeetha G, Shweta P. Efficacy of Levamisole in Children with frequently relapsing and steroid dependant nephrotic syndrome. Indian Pediatr May 15, 2014;51.

Khalid A, Khalid M, Ghannam A. Experience with Levamisole in frequently relapsing and steroid dependant nephrotic syndrome. Pediatr Nephrol Feb. 2006;21(2):201–5. Epub.

Madani Abbas, Seyed M, Fereshteh N, Rozik H, Mastanesh M, Parvin M. Nematollah Effect of Levamisole in steroid dependant nephrotic syndrome. Am J Kidney Dis 2010;4:296–9.

Khalid A, Grisaru S, Stephen D, Arbus G. Levamisole vs. Cyclophosphamide for frequent-relapsing steroid-dependent nephrotic syndrome. Clin Nephrol Oct.2001;54(4):289–94.

Basu B, Pandey R, Mahapatra TK, Mondal N, Schaefer F. Efficacy and safety of mycophenolate versus levamisole in children and adolescents with idiopathic nephrotic syndrome: results of a randomized clinical trial. Am J Kidney Dis June 9, 2015. http://dx.doi.org/10.1053/j.ajkd.2015.04.048. pii: S0272-6386(15)00762-3, [Epub ahead of print].

Hogg Ronald J, Fitzgibbons Lisa, Bruck Joy, Bunke Martin, Ault Bettina, Baqi Noosha, et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol CJASN November 2006;1(6):1173–8.

Gellermann Jutta, Weber Lutz, Pape Lars, Tonshoff Burkhard, Hoyer Peter, Querfeld Uwe, for the Gesellschaft für Pädiatrische Nephrologie (GPN). Mycophenolate mofetil versus cyclosporine A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 2013 Oct.;24(10):1689–97.